Cargando…
Should We Use PPAR Agonists to Reduce Cardiovascular Risk?
Trials of peroxisome proliferator-activated receptor (PPAR) agonists have shown mixed results for cardiovascular prevention. Fibrates are PPAR- [Formula: see text] agonists that act primarily to improve dyslipidemia. Based on low- and high-density lipoprotein cholesterol (LDL and HDL) effects, gemfi...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Hindawi Publishing Corporation
2008
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2234387/ https://www.ncbi.nlm.nih.gov/pubmed/18288293 http://dx.doi.org/10.1155/2008/891425 |